Special Issue "Next Generation Sequencing Approaches in Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 April 2015)
Prof. Dr. Camile S. Farah
Head, Oral Oncology Research Program, UQ Centre for Clinical Research, The University of Queensland, Royal Brisbane & Women’s Hospital, Herston, Qld 4029, Australia
Website | E-Mail
Interests: biomarkers of oral cancer and oral epithelial dysplasia; oral oncology; personalized medicine; next generation sequencing; immunohistochemistry; molecular diagnostics; molecular tumour stratification; microRNA; optical biopsy; molecular imaging
Next generation sequencing is revolutionizing the way in which we interrogate the human genome and ask probing clinical questions. Nowhere is this currently more palpable than in oncology. Next generation sequencing has enabled unbiased cancer genome sequencing in order to screen and search for new cancer genes at an unprecedented scale. The uptake of rapid, scalable and high-throughput sequencing approaches continues to rise, while costs continue to fall. As the intersection between genomic medicine and pharmaceutical therapy converges, patients suffering from cancer are benefiting from the druggable genome and the extensive research activity in this emerging field. Next generation sequencing approaches in oncology are helping forge the future of personalized medicine at an unprecedented rate, although much work remains to be undertaken before the latter is common practice and exerts maximum benefit to our patients. This Special Issue explores the ever-expanding field of next generation sequencing, particularly as it relates to its application in cancer research discovery, cancer care, and the wider field of oncology.
Dr. Camile S Farah
Dr. William Chi-shing Cho
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer biomarkers
- clinical trials
- circulating biomarkers
- copy number variation
- genome-wide association studies
- massively parallel sequencing
- molecular diagnostics
- molecular pathology
- next-generation sequencing
- deep sequencing
- non-coding RNAs
- personalized medicine
- precision medicine
- single nucleotide polymorphism
- single cell sequencing
- targeted therapy
- translational medicine